I think the tie up with Promega, the move into Therapeutics, and the exosome space in general will see this company substantially re-rated this year.
Sure, a capital raise is likely.....and knowing David Williams he'd probably like to increase his exposure....but even with that occurring, the stock could easily reach a $200mln mkt cap this year.
If you're waiting for the cap raise, you may miss the ride.
I think the tie up with Promega, the move into Therapeutics, and...
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
52.0¢ |
Change
-0.010(1.89%) |
Mkt cap ! $48.77M | |||
| Open | High | Low | Value | Volume |
| 52.0¢ | 53.0¢ | 52.0¢ | $14.46K | 27.32K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 12673 | 52.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 53.0¢ | 2654 | 2 |
View Market Depth
| Last trade - 11.50am 13/05/2024 (20 minute delay) ? |
| IIQ (ASX) Chart |